Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate ow.ly/n3nO50Q6KY5

Join us today at 3pm CET / 9am ET for a webcast discussing the U.S. FDA approval of the Company’s chikungunya vaccine ow.ly/coEf50Q6RIz

EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment ow.ly/Cm4150QbnGL

MEP Radan Kanev opened the panel discussion during our “Outbreak Diseases: A Sudden Risk, A Constant Threat” event held last month at the European Parliament. #InfectiousDiseases #Prevention #Science #EU #Policy

Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® ow.ly/P20550QeSA8

Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15 ow.ly/ltjI50QfgYT

#FBF: Mr. Olivier Girard - Head of the Medical Counter-Measures Unit,EU HERA - discussing HERA's current focus at our “Outbreak Diseases: A Sudden Risk, A Constant Threat” event held in October at the European Parliament. #InfectiousDiseases #Prevention #Science #EU #Policy

Congrats to our partner Instituto Butantan for their submission to the Brazilian health regulatory agency Anvisa. Through the OPEN initiative for joint assessment of medicines with the EMA, Anvisa will evaluate the application to register our chikungunya vaccine candidate in Brazil

At Valneva, we are active in the fight against neglected tropical diseases. Join us - #UniteActEliminate. #WorldNTDDay #BeatNTDs worldntdday.org

Valneva Announces Sale of Priority Review Voucher for $103 Million valneva.com/press-release/…

U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ® valneva.com/press-release/…

Did you know #MosquitoBorneDiseases affect up to one in 10 people globally? Warming climates extend mosquito seasons, spreading diseases like #chikungunya worldwide. To learn more, check out our article here: bitly.ws/3bZKp #ClimateChange

🏆 Valneva was recognized not once, but TWICE, at Scotland’s Life Sciences Awards 2024. Congratulations to our colleagues in Scotland for the hard work that led to their award wins in the Outstanding Skills Development & Innovation – Pharm Services and Drug Discovery categories!

Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook valneva.com/press-release/… ➡️ Find more year-end publications in Valneva’s 2023 Annual Reporting Hub: valneva.com/2023-annual-re…

Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C. valneva.com/press-release/…

In 2023: ➡️ 100% of the energy contracted for our manufacturing and R&D sites was of renewable origin ➡️ 56% of our workforce was women ➡️ a new sustainability governance model was implemented at Valneva Read more in our 2023 Sustainability Report: ow.ly/n1Km50R0Np1

Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate valneva.com/press-release/…

We’re at #WVCUSA today and will be hosting an interactive roundtable on #chikungya and #zika. Come join us, and don’t forget to also drop by booth #433!

🏆 We are very pleased to announce that Valneva has won for Best Prophylactic Vaccine at this year’s Vaccine Industry Excellence (VIE) Awards! We're honored to receive this recognition of our chikungunya vaccine. #WVCDC #WVCUSA World Vaccine Congress

Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine ow.ly/G3gh50RCSAY